170 related articles for article (PubMed ID: 17519790)
1. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients.
Foote CJ; Greer W; Kiberd B; Fraser A; Lawen J; Nashan B; Belitsky P
Transplantation; 2007 May; 83(10):1380-4. PubMed ID: 17519790
[TBL] [Abstract][Full Text] [Related]
2. MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients.
Foote CJ; Greer W; Kiberd BA; Fraser A; Lawen J; Nashan B; Belitsky P
Transplant Proc; 2006 Nov; 38(9):2847-9. PubMed ID: 17112845
[TBL] [Abstract][Full Text] [Related]
3. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
[TBL] [Abstract][Full Text] [Related]
4. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
[TBL] [Abstract][Full Text] [Related]
5. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients.
Kuzuya T; Kobayashi T; Moriyama N; Nagasaka T; Yokoyama I; Uchida K; Nakao A; Nabeshima T
Transplantation; 2003 Sep; 76(5):865-8. PubMed ID: 14501869
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
Mendes J; Martinho A; Simoes O; Mota A; Breitenfeld L; Pais L
Transplant Proc; 2009 Apr; 41(3):840-2. PubMed ID: 19376366
[TBL] [Abstract][Full Text] [Related]
7. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
[TBL] [Abstract][Full Text] [Related]
8. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
9. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
Yi SY; Hong KS; Lim HS; Chung JY; Oh DS; Kim JR; Jung HR; Cho JY; Yu KS; Jang IJ; Shin SG
Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
Brunet M; Crespo M; Millán O; Serón D; Torregrosa V; Jiménez O; Moreso F; Martorell J; Grinyo JM; Oppenheimer F
Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
[TBL] [Abstract][Full Text] [Related]
11. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
John U; Ullrich S; Roskos M; Misselwitz J
Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
[TBL] [Abstract][Full Text] [Related]
12. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?
Singh R; Srivastava A; Kapoor R; Mittal RD
J Clin Pharmacol; 2011 Apr; 51(4):603-15. PubMed ID: 20571034
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms.
Li D; Gui R; Li J; Huang Z; Nie X
Transplant Proc; 2006 Nov; 38(9):2850-2. PubMed ID: 17112846
[TBL] [Abstract][Full Text] [Related]
16. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
[TBL] [Abstract][Full Text] [Related]
17. MDR1 C3435T polymorphism in patients with breast cancer.
Turgut S; Yaren A; Kursunluoglu R; Turgut G
Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
[TBL] [Abstract][Full Text] [Related]
18. ABCB1 G2677 allele is associated with high dose requirement of cyclosporin A to prevent renal allograft rejection in North India.
Singh R; Kesarwani P; Srivastava A; Mittal RD
Arch Med Res; 2008 Oct; 39(7):695-701. PubMed ID: 18760199
[TBL] [Abstract][Full Text] [Related]
19. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
Akhlaghi F; Gonzalez L; Trull AK
J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
[TBL] [Abstract][Full Text] [Related]
20. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements.
Fredericks S; Jorga A; MacPhee IA; Reboux S; Shiferaw E; Moreton M; Carter ND; Holt DW; Johnston A
Clin Transplant; 2007; 21(2):252-7. PubMed ID: 17425754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
